Results 31 to 40 of about 1,456,287 (196)

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma.

Annals of Oncology, 2020
BACKGROUND Recent clinical trials demonstrated safety and efficacy of neoadjuvant dabrafenib and trametinib (DT) among patients with surgically resectable clinical stage III BRAFV600E/K mutant melanoma. Although patients achieving a complete pathological
M. Tetzlaff, C. Adhikari, S. Lo, R. Rawson, R. Rawson, R. Amaria, A. Menzies, J. Wilmott, P. Ferguson, P. Ferguson, M. Ross, A. Spillane, K. Vu, Junsheng Ma, Jing Ning, L. Haydu, R. Saw, R. Saw, J. Wargo, H. Tawbi, J. Gershenwald, G. Long, Michael A. Davies, R. Scolyer, R. Scolyer   +24 more
semanticscholar   +1 more source

Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean? [PDF]

, 2015
BACKGROUND: Neoadjuvant breast cancer trials are important for speeding up the introduction of new treatments for patients with early breast cancer and for the highly productive translational research which they facilitate.
Abraham, Jean, Dunn, Janet, Earl, Helena, Gounaris, Ioannis, Hiller, Louise, Provenzano, Elena, Vallier, Anne-Laure   +6 more
core   +3 more sources

Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer [PDF]

, 2019
Background: In patients who have had axillary nodal metastasis diagnosed prior to neoadjuvant chemotherapy for breast cancer, there is little consensus on how to manage the axilla subsequently.
A Gangi, AB Tadros, AM Fowler, AM Kelly, Andrew Evans, AU Buzdar, B Fisher, Colin A. Purdie, DN Krag, Douglas Adamson, E. Jane Macaskill, EA Eisenhauer, EP Mamounas, HM Kuerer, J-M Classe, JC Boughey, JC Boughey, JC Boughey, JF Boileau, JM Dixon, KK Hunt, KS Nason, LM Mobbs, MB Lobbes, Nazleen Muhammad Gowdh, R Alvarado, R Croshaw, RJ Schipper, S Sahoo, Samia Al-Hattali, Sarah J. Vinnicombe, Sharon Armstrong, SJ De Los, SR Tee, T Kuehn, TM Breslin   +35 more
core   +2 more sources

Chronic thoracic hemisection spinal cord injury in adult rats induces a progressive decline in transmission from uninjured fibers to lumbar motoneurons [PDF]

, 2008
Although most spinal cord injuries are anatomically incomplete, only limited functional recovery has been observed in people and rats with partial lesions.
Arko Ghosh, Arsen Hunanyan, Damien D. Pearse, James W. Fawcett, John K. Robinson, Li Lou, Lisa Schnell, Lorne M. Mendell, Martin E. Schwab, Roobeh Golshani, Victor L. Arvanian   +10 more
core   +2 more sources

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study [PDF]

, 2019
Background Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. Methods Patients with primary triple
Apolone G., Bianchi G. V., Cazzaniga M. E., Colombo M. P., Cosimo S. D., Crippa F., de Braud F., De Santis M. C., Folli S., Generali D., Gulino A., Mariani L., Moretti A., Nicola M. D., Paolini B., Scaperrotta G., Torri V., Tripodo C., Verde N. L.   +18 more
core   +2 more sources

NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy

Scientific Reports, 2023
Neoadjuvant chemotherapy (NAC) is a frequently utilized approach to treat locally advanced breast cancer, but, unfortunately, a subset of tumors fails to undergo complete pathological response. Apoptosis and therapy-induced senescence (TIS) are both cell
S. Al Shboul, Mohammed El-Sadoni, Ahmad Alhesa, Nisreen Abu Shahin, Dua Abuquteish, Ola Abu Al Karsaneh, Elham Alsharaiah, Mohammad A. Ismail, Liliya Tyutyunyk‐Massey, M. Alotaibi, Victoria Neely, H. Harada, T. Saleh   +12 more
semanticscholar   +1 more source

Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer [PDF]

, 2005
Background: Induct ion chemotherapy followed by surgical resection or definitive radiotherapy for patients affected by stage IIIA N2 bulky non-small cell lung cancer (NSCLC) has been investigated in several trials.
BORDONARO R., CASTORINA S, GIANNITTO GC, GIUFFRIDA D, LA VENIA G, MARLETTA F, PAPPALARDO A, POTENZA, E, RUSSO, Antonio, SAITA S, VINCENZI B   +10 more
core   +1 more source

Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study

EClinicalMedicine, 2023
Summary Background Accurate identification of pCR to neoadjuvant chemotherapy (NAC) is essential for determining appropriate surgery strategy and guiding resection extent in breast cancer. However, a non-invasive tool to predict pCR accurately is lacking.
Yuhong Huang, T. Zhu, Xiao-Ling Zhang, Wei Li, Xingxing Zheng, M. Cheng, F. Ji, Liulu Zhang, Ciqiu Yang, Zhi-Yong Wu, G. Ye, Ying Lin, Kun Wang   +12 more
semanticscholar   +1 more source

Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report [PDF]

, 2010
We report a 49-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen.
Jun Wang, George W Saukel, Carlos A Garberoglio, Wichit Srikureja, Chung-Tsen Hsueh   +4 more
core   +1 more source

The prognostic and predictive power of redox rotein expression for anthracycline-based chemotherapy response in locally advanced breast cancer [PDF]

, 2012
Neoadjuvant chemotherapy has become the standard of care for locally advanced primary breast cancer. Anthracycline-based regimens have proven to be one of the most effective treatments in this setting.
A Ravid, AE Ring, AF Howie, Ahmad Al-Attar, B Chevallier, BK Arun, C Cadenas, Caroline M Woolston, CM Woolston, CM Woolston, D Mayr, D Ravi, D Shin, E Junn, HM Kuerer, I Muller, Ian O Ellis, J Huang, JA Mobley, JA Moscow, JD Pennington, JH Jeon, JO Park, L Behrend, L Gilbert, L Moureau-Zabotto, LC Alpert, Lei Zhang, LM Butler, LM Forrester, LM Mcshane, M Valko, MM Montano, Mohamed Shehata, S Toyokuni, Sarah J Storr, SH Han, SM Mense, Stephen Y Chan, Stewart G Martin, Y Nakanishi   +40 more
core   +2 more sources